Novavax Inc (NVAX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Novavax Inc stock (NVAX) is currently trading at $9.34. Novavax Inc PE ratio is 3.73. Novavax Inc PS ratio (Price-to-Sales) is 1.40. Analyst consensus price target for NVAX is $13.78. WallStSmart rates NVAX as Hold.
- NVAX PE ratio analysis and historical PE chart
- NVAX PS ratio (Price-to-Sales) history and trend
- NVAX intrinsic value — DCF, Graham Number, EPV models
- NVAX stock price prediction 2025 2026 2027 2028 2029 2030
- NVAX fair value vs current price
- NVAX insider transactions and insider buying
- Is NVAX undervalued or overvalued?
- Novavax Inc financial analysis — revenue, earnings, cash flow
- NVAX Piotroski F-Score and Altman Z-Score
- NVAX analyst price target and Smart Rating
Novavax Inc
📊 No data available
Try selecting a different time range
NVAX Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Novavax Inc (NVAX)
NVAX trades at a significant discount to its Graham intrinsic value of $17.54, offering a 49% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Novavax Inc (NVAX) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in peg ratio, price/sales, revenue growth. Concerns around return on equity and price/book. Fundamentals are solid but monitor weak areas for improvement.
Novavax Inc (NVAX) Key Strengths (5)
Revenue surging 66.60% year-over-year
Keeps $39 of every $100 in revenue as net profit
70.09% of shares held by major funds and institutions
Good growth relative to its price
Paying $1.40 for every $1 of annual revenue
Supporting Valuation Data
Novavax Inc (NVAX) Areas to Watch (5)
Company is destroying shareholder value
Earnings declining -38.10%, profits shrinking
Very expensive at 33.2x book value
Thin operating margins with cost pressures present
Small-cap company with higher risk but more growth potential
Novavax Inc (NVAX) Detailed Analysis Report
Overall Assessment
This company scores 56/100 in our Smart Analysis, earning a C grade. Out of 10 metrics analyzed, 5 register as strengths (avg 9.2/10) while 5 fall into concern territory (avg 2.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth, Profit Margin, Institutional Own.. Valuation metrics including PEG Ratio (1.32), Price/Sales (1.40) suggest the stock is attractively priced. Profitability is solid with Profit Margin at 39.20%. Growth metrics are encouraging with Revenue Growth at 66.60%.
The Bear Case
The primary concerns are Return on Equity, EPS Growth, Price/Book. Some valuation metrics including Price/Book (33.20) suggest expensive pricing. Growth concerns include EPS Growth at -38.10%, which may limit upside. Profitability pressure is visible in Return on Equity at -898.00%, Operating Margin at 14.20%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -898.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 66.60% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. Strengths and concerns are roughly balanced. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (Revenue Growth, Profit Margin) and negatives (Return on Equity, EPS Growth). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
NVAX Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
NVAX's Price-to-Sales ratio of 1.40x trades at a deep discount to its historical average of 237.26x (0th percentile). The current valuation is 100% below its historical high of 1414.99x set in Apr 2010, and 0% above its historical low of 1.4x in Mar 2026.
WallStSmart Analysis Synopsis
Data-driven financial summary for Novavax Inc (NVAX) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Novavax Inc is a strong growth company balancing expansion with improving profitability. Revenue reached 1.1B with 67% growth year-over-year. Profit margins are strong at 39.2%, reflecting pricing power and operational efficiency.
Key Findings
Revenue growing at 67% YoY, reaching 1.1B. This pace significantly outperforms most BIOTECHNOLOGY peers.
Debt-to-equity ratio of -1.60 indicates a conservative balance sheet with 268M in cash.
Free cash flow is -42M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Novavax Inc maintain 67%+ revenue growth, or will competition slow it down?
Volatility is elevated with a beta of 2.63, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Novavax Inc.
Bottom Line
Novavax Inc offers an attractive blend of growth (67% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Novavax Inc(NVAX)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Novavax, Inc., a biotechnology company, focuses on the discovery, development and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company is headquartered in Gaithersburg, Maryland.